# C_2011129EN.01000301.xml

| 30.4.2011 | EN | Official Journal of the European Union | C 129/3 |
| --- | --- | --- | --- |

30.4.2011

EN

Official Journal of the European Union

C 129/3

---

Prior notification of a concentration

(Case COMP/M.6113 — DSM/Sinochem/JV)

(Text with EEA relevance)

2011/C 129/04

| 1. | On 8 April 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Koninklijke DSM NV (the Netherlands) and Sinochem Group (China) create a joint venture within the meaning of Article 3(1)(b) of the Merger Regulation by way of purchase of shares in the existing anti-infectives business of Koninklijke DSM NV (‘DAI’). |
| --- | --- |

1.

On 8 April 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Koninklijke DSM NV (the Netherlands) and Sinochem Group (China) create a joint venture within the meaning of Article 3(1)(b) of the Merger Regulation by way of purchase of shares in the existing anti-infectives business of Koninklijke DSM NV (‘DAI’).

1

| 2. | The business activities of the undertakings concerned are:






  — | for Koninklijke DSM NV: human and animal nutrition, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Koninklijke DSM NV: human and animal nutrition, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics,

| — | for Sinochem Group: agriculture, energy, chemical, real estate and finance, |
| --- | --- |

—

for Sinochem Group: agriculture, energy, chemical, real estate and finance,

| — | for DAI: production of beta-lactam antibiotics, generic pharmaceutical products, other anti-infective products intended to be marketed and sold as active pharmaceutical ingredients or as finished dosage products. |
| --- | --- |

—

for DAI: production of beta-lactam antibiotics, generic pharmaceutical products, other anti-infective products intended to be marketed and sold as active pharmaceutical ingredients or as finished dosage products.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6113 — DSM/Sinochem/JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6113 — DSM/Sinochem/JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---